Copyright © 2021. Inderes Oyj. All rights reserved.

Redeye regards Genovis’ Q1’22 report as solid and is encouraged to see continuously strong growth in the Enzyme business. Adjusted for the SEK 10m relating to the license agreement with Selecta, sales were in line with our expectations (SEK 22.6m versus our estimated SEK 22.9m).

Lähde: Finwire News

Genovis AB provides enzymes and technologies for analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce and market tools for developing new drugs and diagnostics. The Genovis product line comprises of GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company serves mainly the medical device and pharmaceutical industries.